Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Baptist Health Oncologist Rohan Garje Recognized for National Leadership in Cancer Treatment Guidelines
Clinical trials continue to inform how physicians treat advanced prostate cancer. The American Society of Clinical Oncology (ASCO) develops guidelines to help oncologists evaluate new evidence and apply it to clinical practice
Clinical Scorecard: ASCO Guideline Development for Advanced Prostate Cancer
At a Glance
Category
Detail
Condition
Advanced prostate cancer, with the 2025 ASCO update focused on metastatic castration-resistant prostate cancer (mCRPC).
Key Mechanisms
The source describes mCRPC as prostate cancer that continues to progress despite treatment to suppress testosterone. ASCO recommendations are based on available clinical evidence and may be revised as new research becomes available.
Target Population
Physicians treating patients with advanced prostate cancer, including patients with mCRPC; the article also discusses biomarker guidance for patients with advanced cancer.
Care Setting
Not specified in the source.
Key Highlights
ASCO issued major updates to its metastatic prostate cancer treatment recommendations in 2022 and 2025.
The 2025 update focuses on systemic therapy for mCRPC and was published in the Journal of Clinical Oncology with Rohan Garje as lead author.
ASCO uses a living guideline model in which experts review emerging evidence and determine whether existing recommendations warrant revision.
ASCO endorsed a College of American Pathologists guideline on mismatch repair and microsatellite instability testing in 2023; the source says these biomarkers can help identify patients who are candidates for immune checkpoint inhibitor therapy.
Guideline-Based Recommendations
Diagnosis
The article reports ASCO's 2023 endorsement of a College of American Pathologists guideline on mismatch repair and microsatellite instability testing.
Management
The 2025 ASCO update provides recommendations on systemic therapy for mCRPC based on available clinical evidence.
The article does not specify individual drug regimens or treatment sequences.
Monitoring & Follow-up
ASCO experts review emerging evidence under the living guideline model and determine whether changes to existing recommendations are warranted; the article does not describe patient-monitoring recommendations.
Risks
The article does not describe specific treatment risks or adverse effects.
Patient & Prescribing Data
Patients with metastatic castration-resistant prostate cancer and other patients with advanced prostate cancer addressed by ASCO guidance.
The article reports that ASCO's 2025 update concerns systemic therapy for mCRPC but does not provide specific prescribing details.
Clinical Best Practices
The article reports that ASCO's 2025 update provides evidence-based systemic therapy recommendations for mCRPC.
The article describes ASCO's living guideline process for reviewing emerging evidence and considering revisions to recommendations.
The article reports that mismatch repair and microsatellite instability testing guidance can help identify patients who are candidates for immune checkpoint inhibitor therapy.
